Abstracts

322 – Functional Study of N6-Methyladenosine (m6A) Machinery in HIV Infection of Primary CD4+ T Cells

Background N6-methyladenosine (m6A) modification is the most prevalent post-transcriptional modification of cellular and viral RNA and is critical to the regulation of its localization, stability, and translation. The core m6A machinery consists of writers that deposit the modification, erasers that remove it and readers that respond to the presence of m6A on RNA. Previous studies…

328 – The Role of Capsid-Host Interaction on Lentiviral Evolution

Background Primate lentiviruses (SIVs) have been evolving with their hosts for millions of years. Capsid-interacting dependency and restriction factors are known to play a key role in HIV replication. Small changes in viral capsid sequence can alter these interactions for the benefit of the virus (e.g. to escape a restriction factor). Previous work has focused…

321 – Direct Sequencing of Full-Length HIV-1 RNA Reveals the Functional Significance of Site-Specific m6As

Background While the significance of chemical modifications on RNA has been well established, their specific roles in HIV-1 replication remain unclear and, at times, controversial. Previous studies have provided only low-resolution, type-specific RNA modification site mapping and have relied on indirect analyses of phenotypic effects through the overexpression or knockdown (knockout) of host effectors. These…

188 – Effect of a Person-Centered Care Intervention on Reengagement After Care Interruptions in Zambia

Background Poor client-provider interactions lead to reinforcing cycles of treatment interruptions (TIs) and fear of return, undermining sustained retention. We previously demonstrated a multicomponent person-centered care intervention (PCCi) targeting healthcare worker (HCW) behavior improved client experience and retention in care. To understand mechanisms of improved retention, we evaluated the effect of PCCi on return after…

107 – RIO: A Randomised Placebo-Controlled Study of 2 LS-bNAbs in People Treated in Early HIV

Background The extent to which LS-broadly neutralizing antibodies (LS-bNAbs) maintain viral control off ART remains unknown. RIO tested the frequency and durability of viral control of LS-bNAbs compared with placebo in people with treated early HIV.   Methods RIO is a double-blind randomised 1:1 placebo-controlled trial designed to investigate viral control in the absence of ART. Virally-suppressed participants (aged 18-60) who started ART during early HIV received up to two intravenous…

204A – Switch to DOR/ISL (100/0.25 mg) QD From BIC/FTC/TAF: A Blinded Phase III Study in Adults With HIV-1

Background Doravirine (DOR), an NNRTI, and islatravir (ISL), an investigational nucleoside reverse transcriptase translocation inhibitor, have complementary mechanisms of action and resistance profiles. MK-8591A-052 is an ongoing phase 3 study evaluating the efficacy and safety of switching from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) to DOR/ISL (100/0.25 mg), a once-daily single-tablet regimen. Declines in CD4 T-cell and lymphocyte counts…

204B – Switch to DOR/ISL (100/0.25 mg) QD From Oral ART: An Open-Label Phase III Study in Adults With HIV-1

Background Doravirine (DOR), a NNRTI, and islatravir (ISL), an investigational nucleoside reverse transcriptase translocation inhibitor, have complementary mechanisms of action and resistance profiles. MK-8591A-051 is a phase 3 study evaluating the efficacy and safety of switching from oral ART to DOR/ISL (100/0.25 mg), a once-daily single-tablet regimen. Declines in CD4 and total lymphocyte counts were…

201 – Tecovirimat Is Safe but Not Efficacious in People With Clade II Mpox

Background Mpox has caused two international public health emergencies; no therapies have established efficacy. ACTG A5418/STOMP is a phase 3 randomized placebo-controlled double-blind trial evaluating the efficacy of tecovirimat, an antiviral with animal data supporting its use for orthopox infections.  Methods Participants ≥18 years with symptomatic laboratory-confirmed or presumptive mpox <14 days were randomized 2:1…